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Abstract 
Fumarylacetoacetate (FAA) is a downstream metabolite of phenylalanine catabolism. In Human 
Type 1 Tyrosinemia a deletion of the enzyme that breaks down this compound leads to a toxic 
build up that leads to acute liver and kidney failure. FAA is used to test the activity of a drug 
used liver repopulation therapy. This project aims to synthesize this compound using enzyme 
extracts from the filamentous fungi ​Aspergillus nidulans. ​The fungus is grown on a carbon 
source, phenylacetic acid, which induces expression of enzymes in the phenylalanine catabolic 
pathway. The enzymes are then extracted from the cultures, purified, and used in an enzyme 
assay converting the metabolite homogentisate (HGA) to maleylacetoacetate (MAA). MAA is 
then isomerized to FAA via the addition of metaphosphoric acid (MPA).​ ​This report outlines 
attempts to synthesize this compound and the troubleshooting techniques employed. 
 
Introduction 
     The phylum of fungi Ascomycota consists of over 30,000 species including both unicellular 
and multicellular organisms[19]. Ascomycetes have both vegetative and reproductive stages, and 
spend most of their life cycles with haploid genomes, although they can be diploid during certain 
life phases [9, 19]. Multicellular ascomycetes, such as the filamentous fungi ​Aspergillus 
nidulans​, have drastically different morphologies during different life cycles and can alternate 
between these depending on outstanding conditions (Figure 1). When submerged in liquid 
culture, ​Aspergillus nidulans​ exists as vegetative bodies collectively known as mycelium. These 
cells are generally haploid, but can fuse with other genetically distinct hyphae to form either 
binucleate, or occasionally diploid mononucleated cells (Figure 1). When a colony of mycelium 
is exposed to air, they undergo conidiation [19]. This process leads to the production of asexual 
spores known as conidia. Ascomycetes can also undergo sexual reproduction during which 
fruiting bodies known as cleistothecia containing meiotically derived ascospores form (Figure 1). 
Cleistothecia are generally homothallic, meaning that ascospores from one fruiting body will 
generally mate with other spores within the same mycelium [27].  
 
Figure 1. Life cycle of ​A. nidulans​ taken from Timberlake and Marshall [27]. 
 
     Some ascomycete species are pathogens, causing human illnesses such as pneumonia, while 
others are notable for their utility. Many are used in food and drink production, such as bakers 
and brewers yeasts. Other ascomycetes are used in medical and research settings for producing 
enzymes and antibiotics such as penicillin [19, 27]. In research, ascomycetous fungi are valuable 
as model organisms for the study of biological processes, with some of the most common model 
organisms in molecular and cell biology being ​Saccharomyces cerevisiae​ and ​Neurospora 
crassa. Aspergillus nidulans​ is a filamentous fungus that is  used as model organism for the 
study of multicellular eukaryotic systems[19, 27]. 
     ​Aspergillus nidulans​ possesses several characteristics that make it particularly suited to 
genetic analysis and manipulation. For example, a haploid, single nucleate mycelium 
(homokaryon) can fuse with hyphae from another, genetically distinct homokaryon to form cells 
that contain the nuclei of both parents (heterokaryon) (Figure 1). This property means that two 
genetically distinct strains, if combined, will spontaneously form heterokaryon that can be easily 
isolated by simple complementation experiments. ​A. nidulans​ is also very susceptible to DNA 
mediated transformation, which can induce site directed mutations that can also be detected by 
complementation tests [20, 23, 27, 28]. ​A. nidulan’s​ relatively fast life cycle and simple 
nutritional needs further contribute to its utility as a model organism for studying biological 
processes in multicellular eukaryotes.  
     One such use has been illustrated by Fernández-Cañón, J. M. and Peñalva, M. A, who 
employed ​A. nidulans​ to characterize several of the genes encoded in the phenylalanine (Phe) 
metabolic pathway (Figure 2). ​Aspergillus nidulans ​is well suited for the study of catabolic 
pathways because each pathway is only induced in the presence of the proper transcriptional 
activator, and therefore it is possible to control gene expression in a pathway via the addition or 
withdrawal of specific nutrients [20, 22, 23, 28].  
       Genetically based defects in the enzymes of a metabolic pathway characterize autosomal 
recessive disorders that fall under the category of ‘inborn errors of metabolism’[28]. These 
genetic diseases are of great interest to gene therapy researchers because they are often caused by 
a single mutated gene encoding one of the enzymes in the pathway. This makes them much 
easier to target when compared to many other genetically based diseases which have numerous 
environmental influencers in addition to mutated genes, all of which may directly or indirectly 
contribute to a disease phenotype.  
     The first inborn error of metabolism ever classified, alkaptonuria, results from a buildup of 
the intermediate phenylalanine metabolite homogentisate [23]. The buildup is caused by a 
mutation in the gene encoding homogentisate 1,2-dioxygenase (HGD), enzyme IV in the 
phenylalanine metabolic pathway (Figure 2). The disease has relatively mild symptoms, 
including black urine, and an increased risk of arthritis [23, 28]. Mutations in other enzymes in 
this pathway have far more severe effects, leading to diseases such as phenylketonuria (PKU) 
and tyrosinemia which lead to rapid neurological deterioration and often death soon after birth if 
not treated [Figure 2].  
 
Figure 2. The phenylalanine pathway for humans and ​A. nidulans. ​The phenylacetate 
pathway is only present in ​A. nidulans​. Numerals correspond to disorders caused by 
knockout of each enzyme: I, phenylketonuria and phenylalaninaemias; II, type II 
tyrosinemia; III type III tyrosinemia; IV alkaptonuria; V hereditary type I tyrosinemia. 
Figure taken from Fernández-Cañón and Peñalva [28]​.  
  
     Fernández-Cañón, J. M. and Peñalva, M. A. were interested in studying inborn errors of 
metabolism in the phenylalanine pathway. They constructed a protocol for growing ​A. nidulans 
and extracting the enzymes involved in phenylalanine pathway for further study [20, 22, 23, 28]. 
The procedure included creating strains of ​A. nidulans ​deficient in one of the enzymes in the 
pathway via DNA mediated transformation, termed a knockout strain. Protein extracts from these 
strains are used in spectrophotometric enzyme assays designed to detect, analyze, and utilize 
enzymatic activity [20, 22, 23, 28].  
      One use for the protocols they created is the production of fumarylacetoacetate (FAA), an 
intermediate metabolite in the Phe catabolic pathway that is broken down into its components by 
the fumarylacetoacetate hydrolase (FAH) enzyme [28]. FAA is not available commercially, and 
it must therefore be made in the lab if required. This is accomplished by growing a strain of ​A. 
nidulans​ deficient in the FAH enzyme under nutritional conditions that activate the Phe pathway. 
Activation leads to increased expression of the enzymes encoded in the pathway. The enzymes 
are then extracted and purified. This extract is then used to convert the commercially available 
upstream metabolite homogentisic acid (HGA) into fumarylacetoacetate (FAA), the desired 
product [28].  
     Fumarylacetoacetate (FAA) is clinically significant as the compound that accumulates in a 
rare genetic disorder known as human type I tyrosinemia [4,5]. This toxic build up, caused by a 
deficiency in the phenylalanine metabolic enzyme FAH, leads to cirrhosis, human hepatocellular 
carcinoma, and kidney failure [4,5].  Patients with HT1 inherit a mutated copy of the ​fah ​gene 
from both parents making them homozygous recessive individuals.  
     FAA  is also of interest in research for drug development in liver repopulation therapy. This 
can be seen in a recent paper published in Science Translational Medicine [5]. In this article, 
Nygaard et al. utilize the toxic nature of FAA build up in order to confer a selective advantage to 
genetically modified cells transplanted into a diseased liver. Liver repopulation therapy is the 
process by which patient cells that are corrected for a given mutation are implanted into a 
diseased liver with the intention that they will repopulate the liver with healthy cells [29]. In 
order for this method to be successful, the transplanted cells a must have a strong selective 
advantage over the host cells so that they can reach sufficient replication levels to nullify the 
disease symptoms.  In type 1 tyrosinemia, a deficiency in the enzyme FAH causes a toxic build 
up of FAA [5, 28, 29]. This disease confers a strong selective advantage to hepatocytes that have 
working FAH enzymes [5, 29]. The approach taken by Nygaard et al. is to introduce an FAH 
inhibiting drug, called CEHPOBA,  to the liver after the transplantation of genetically modified 
cells. The modified cells contain the therapeutic transgene, as well as a shRNA that confers 
resistance to CEHPOBA by blocking enzymatic activity further upstream of FAH in the 
pathway, leading to the build up of a less toxic intermediate metabolite (HGA). Nygaard et al. 
illustrate that this method can be used to confer a selective advantage to transplanted cells 
intended to correct inborn errors of metabolism and other genetic diseases that affect the liver 
[5].  
     The creation of a method to universally confer selective advantage to transplanted cells 
obviously has substantial clinical benefits and further study and optimization of this method is 
therefore warranted. New batches of the drug CEHPOBA need to be tested for effectiveness in 
vitro before being utilized in liver repopulation experiments. The drug is tested in an enzyme 
assay, similar to the assay used in the FAA synthesis protocol, wherein liver extract (generally 
mouse) containing FAH enzyme is combined with FAA and the drug CEHPOBA and placed in a 
spectrophotometer. If absorbance of light at 330 nm decreases over time, then FAH is 
hydrolysing FAA, which absorbs light at this wavelength [22]. In this case it’s activity is 
therefore not being blocked by CEHPOBA. Alternatively, if there is no decrease in the 
absorbance measurement, this indicates that the CEHPOBA is blocking the FAH activity and is 
therefore suitable to be used in repopulation experiments. It is therefore critical to make stocks of 
FAA so that these assays can be run.  
     This thesis project was an attempt to make these FAA stocks. Attempts began in March of 
2017 and as of May 2018 the protocol has still yet to be successfully run from start to finish. The 
following pages describe the basics of the protocol, as well as attempts to troubleshoot this very 
technically challenging process.  
Methods 
This protocol was based off procedures developed and shared by Dr. Fernández-Cañón [22, 23]. 
Fungal spores were stored in a  25% glycerol solution at -80℃. After being thawed, spores were 
grown on solid media plates containing (in g/l) agar (Apex: Bioresearch Products), 20; peptone 
(Bacto​TM ​), 1; malt extract (Bacto​TM ​), 20; glucose (Invitrogen), 15. 50 ul of spore solution was 
added to each media plate. Spores were grown at 37℃ for 2-3 days and then harvested in 30 ml 
of water with Tween80, 0.01% w/v. This solution was vortexed and then stored overnight at 4℃ 
before the spores were spun down at 7500 ​g​ in a Beckman J2-HC centrifuge for 20 minutes and 
resuspended in 30 ml of pure water.  
          6 ml of spores were then inoculated into 400 ml of defined growth media containing (in 
g/l) KP0​4​H​2​ (​Research Products International Corp),​ ​13.6; (NH​4​)​2​S0​4 ​(Millipore Sigma), 2.0; 
MgS0​4​7H​2​0 (Fischer Scientific), 0.25; FeS0​4​7H​2​0 (Acros Organics), 0.0005; ​CuSO​4​.5H​2​O 
(​Fischer Scientific), glucose (Invitrogen), 0.3% w/v; biotin (Fischer BioReagents), 0.001; and 
methionine (Sigma Aldrich), at 5mM final concentration. The pH of this media was adjusted to 7 
via addition of KOH (Fischer Scientific) before inoculation with spores. Cultures were grown for 
18 hours in a New Brunswick Scientific Excella E25 orbital shaker at 250 rpm. After this initial 
growth period, the fungus, now in the form of mycelium, were harvested via filtration, washed 
with 2 l of Milli-Q water, and added to cultures containing all of the previous supplements 
except for glucose and shaken for 1 hour. Phenylacetic acid (Sigma Aldrich) was then added at a 
final concentration of 10 mM. The cultures were grown in the orbital shaker on phenylacetic acid 
as the sole carbon source for 4 hours before once again being harvested via filtration and rinsed 
with 2 l of Milli-Q water. The mycelium was then resuspended in 50 mM potassium phosphate 
buffer pH 7 at a concentration of 1 g mycelia per 10 ml of buffer. ​The mycelia were then 
mechanically broken open via sonication using five 10 second pulses with 1 minute breaks 
between using a Cole Parmer Ultrasonic Processor at 4℃. The resulting lysate was centrifuged at 
13,000 ​g​ ​for 15 min at 4℃ to clear away larger cell debris. This extract was then further clarified 
via passage through a PD-10 desalting column to form the final protein extract.  
       The protein extract was used in an enzyme assay designed to convert homogentisate (HGA) 
into maleylacetoacetate (MAA). The reaction was initially run in a 1 ml pilot reaction before 
moving to the full scale 10 ml reaction. The assay contained HGA (Tokyo Chemical Industry), 2 
mM from 200 mM stock; ascorbic acid (Fischer Scientific), 1 mM from 100 mM stock; FeS0​4 
(Acros Organics) 50 uM from 50 mM stock; protein extract (100 ul for pilot and 2 ml for full 
size reaction), and 50 mM potassium phosphate buffer pH 7 added to bring final volume of 
reaction to desired volume, either 1 ml for the pilot or 10 ml for the full size reaction. The 
reaction was run in a 37℃ water bath with oxygen bubbled in continuously throughout the 
reaction time. The progress of the reaction was monitored in a Thermo Scientific Nanodrop 
2000c Spectrophotometer that tracked the conversion a 290 nm absorbance peak, representing 
HGA into a 330 nm peak, representing MAA. After complete conversion of the 290 nm peak 
into the 330 peak, Metaphosphoric acid (Sigma Aldrich), at 20% w/v was added to precipitate 
out remaining proteins and isomerize MAA to FAA. The acidified mixture was kept overnight at 





     After growing ​Aspergillus nidulans​ in phenylacetic acid to induce the phenylalanine pathway, 
a protein extract was made by breaking open the cells of the mycelium via sonication to release 
the intracellular components including the desired enzyme, homogentisate 1,2-dioxygenase 
(HGD). The extract was purified via centrifugation and passage through a PD-10 desalting 
column. This enzyme extract was then added to a reaction containing HGA, 2 mM from 200 mM 
stock; ascorbic acid, 1 mM from 100 mM stock; FeS0​4 ​ 50 uM from 50 mM stock; protein extract 
(100 ul for pilot and 2 ml for full size reaction), and 50 mM potassium phosphate buffer pH 7 
added to bring the contents of the reaction to the desired volume of 1 ml for the pilot reaction. 
The reaction was run at 37℃ for 250 minutes. Figure 3 shows this first iteration of the enzyme 
assay run in the project. When the HGD enzyme converts homogentisate to maleylacetoacetate, 
the absorbance at 330 nm should increase substantially- from 0 to around 1.35 OD according to 
the published protocols (Dr. Fernández-Cañón). The conversion within this assay fell far short of 
that with the highest absorbance read being 0.45 OD (Figure 3). Another concerning feature of 
this experiment was the amount of time taken for this minimal conversion to take place. 
Fernández-Cañón recalls a reaction time of between 15 to 20 minutes. This reaction was run for 
over two hours and reached levels of product around a third of what was expected (Figure 3). 
This indicates diminished enzyme activity.  
 
Figure 3. Change in absorbance at 330 nm in Nanodrop spectrophotometer for enzyme assay over time​.​ 100 
ul of enzyme extract from​ A. nidulans​ combined with 2mM HGA, 1 mM ascorbate, 50 uM FeS0​4 ​and 
potassium phosphate buffer pH 7, and placed in a 37℃ water bath with oxygen bubbled in for 250 minutes.  
  
     It was thought based on the data in Figure 3 that inadequate amounts of enzyme was extracted 
from the ​A. nidulans. ​It was hypothesized that this was due to inadequate breakage of the tough 
cell walls of the mycelium. In order to extract more enzyme from the mycelia, an alternative 
strategy of mechanical breakage was pursued. This involved using a French Pressure Cell Press, 
a machine that applies pressure up to 20,000 psi on to a sample in order to burst tough cell walls. 
The level of cell lysis was also measured by observing the mycelia under a light microscope 
using DAPI nucleic acid staining. If the DAPI was concentrated in the nucleus of the cells, it was  
taken to mean that lysis had not taken place (Figure 4A). However, if the dye was diffuse then it 
was assumed that the mycelia had burst (Figure 4B)  
     After verifying that the mycelia were properly burst in this way, the enzyme assay was rerun 
under the same conditions as the first iteration to test for increased activity (Figure 5). This 
experiment yielded around the same amount of overall conversion although it was in a shorter 
amount of time. After about 30 minutes, the peak absorbance at 330 nm was reached. Since the 
improved cell lysis measure did not improve yields of product, several other methods of 
increasing the concentration of HGD in the protein extract were attempted. These included 
increasing the amount of spores added liquid culture from 6 ml to 10 ml, increasing the speed at 
which the liquid cultures were shaken during the growth period from 250 rpm to 350 rpm, and 
changing the growth media from a defined to a complex media in the form of Luria Broth 
(Fischer Scientific). All of these measures produced spectrophotometric data that resembled the 
assays shown in Figures 3 and 5 (data not shown). 
 
  
Figure 4. Mycelia stained with DAPI under fluorescent microscope. 4A (left) shows intact mycelia before 
shearing in the French Press. 4B (right) displays burst mycelia after shearing.  
 
 
Figure 5. Second iteration of HGD enzyme assay after enhanced cell lysis methods. 100 ul of enzyme extract 
from​ A. nidulans​ combined with 2mM HGA, 1 mM ascorbate, 50 uM FeS0​4 ​and potassium phosphate buffer 
pH 7, and placed in a 37℃ water bath with oxygen bubbled in for 65 minutes. 
  
       In order to verify that the remaining reactants in the enzyme assay were operating as 
expected, an alternative source of enzyme was pursued. This took the form of a crude extract 
from FAH knockout mouse livers. These were not originally pursued as an enzyme source 
because they do not have the option of a strong induction of the Phe pathway through 
phenylacetic acid, which was one of the biggest appeals of the ​A. nidulans ​model [22, 23]. This 
means that the mouse livers do not produce as much of the required enzyme as the fungus. 
Nevertheless a protein extract was isolated via harvesting 4 mouse livers, homogenizing them in 
a solution of ice cold 0.14 M KCl added at 200% v/v, centrifuging them at 5000 rpm at 4℃, then 
centrifuging the supernatant at 20,000 ​g ​for 20 minutes at 4℃. The assay used for this enzyme 
source was slightly different. The buffer used to bring the reaction to its final volume was 1 M 
Tris at pH 7.4, 50 mM of ascorbate was added as opposed to the usual 100 mM, 1.5 mM of 
HGA, and no source of Fe​2+​ ​ions was added. Under these conditions, the mouse liver extract 
produced no detectable activity (Figure 6). 
 
  
Figure 6. HGD enzyme assay using extract from fah (-/-) mouse liver.​ ​1 ml reaction contained 1 M Tris at pH 
7.4, 50 mM ascorbate, and 1.5 mM of HGA. Reaction was stopped after 20 minutes due to no change in 
absorbance at 330 nm measured in the Nanodrop spectrophotometer. 
  
      Several more assays were run using fungal extracts and several variations on the reaction 
components, including trying a different buffer (Tris instead of potassium phosphate), 
eliminating Fe 2+ ions, and changing the concentration of the substrate HGA (1.5 mM, 2 mM 
and 3 mM). None of these alterations produced an increase in enzyme activity as detected by the 
spectrophotometer (Data not shown). It was therefore hypothesized that perhaps the fungal 
spores, which had been stored at -80℃ for over 15 years, were too old to grow robustly and 
produce adequate amounts of enzyme. In order to address this potential problem, new protein 
extract and mycelium were obtained from the original architect of the protocol, Professor 
Fernández-Cañón, PhD.  
      The new extract was used in the original assay protocol. Figure 7 displays the spectra at the 
beginning and end of the run as well as the change in absorbance over time. This assay showed 
very promising results. The appearance of a product peak at 330 nm indicated that there was high 
enzyme activity in the new extract. These data would suggest that problems with the previous 
assays were indeed an inadequate concentration of enzyme. All of the reactions up to this point 
had been pilot reactions that took place in 1 ml. The full reaction for the synthesis of large 
































Figure 7. Enzyme assay for extract from Dr. Fernández-Cañón.  100 ul of enzyme extract from​ A. nidulans 
combined with 2 mM HGA, 1 mM ascorbate, 50 uM FeS0​4 ​and potassium phosphate buffer pH 7, and placed 
in a 37℃ water bath with oxygen bubbled in for 40 minutes. Progress of the reaction was monitored in a 
Nanodrop spectrophotometer. (A) indicates spectrophotometric readout at the beginning of reaction with 
labels for peaks of the substrate (HGA) and the product (MAA). (B) indicates the spectrum of the enzyme 
assay at 40 minutes. (C ) displays the increase in absorbance at 330 nm over time.  
  
     After this successful pilot reaction, a larger scale reaction was attempted with the same 
enzyme source and reaction conditions. However, when the full scale reaction was run, there was 
once again no significant conversion of HGA to MAA (data not shown). Since it was clear from 
the data collected in the pilot reaction that there was significant activity in the enzyme extract 
(Figure 7), it was hypothesized that some aspect of the reaction setup was impeding the full size 
reaction. For example, the original protocol calls for bubbling oxygen into the reaction mixture 
continuously throughout the course of the assay, however due to the fact that bubbling has the 
potential to denature proteins, an alternative approach to adding oxygen to the reaction was 
pursued. This involved adding all of the reactants except for the protein extract into the reaction 
tube, pumping oxygen into the tube and dissolving it in the reaction mixture via vortexing. The 
reaction was also placed in a metal bead bath to maintain temperature at 37℃ as opposed to the 
traditional water bath. The enzyme extract was then added and the reaction was monitored in the 
spectrophotometer after an additional modification step (Figure 8). Due to the fact that MAA 
will not absorb at 330 nm if it is in too alkaline of a pH, the metaphosphoric acid, which is 
usually added after the reaction is complete, was added at a concentration of 10% v/v to the 
sample before the spectrum was obtained (Figure 8). As it apparent from the spectrum, there was 
no quantitative conversion of HGA to MAA. Another notable feature of the spectrum was the 
HGA peak, which is characteristically at 292 nm had shifted (Figure 8). This was very likely 
caused by the acidification of the mixture before it was placed in the spectrophotometer.  
 
 
Figure 8. Spectrum of 10 ml full size reaction mixture with extract from Dr. Fernández-Cañón. 2 mM HGA, 1 
mM ascorbate, 50 uM FeS0​4 ​and potassium phosphate buffer pH 7, added to reaction tube before oxygen gas 
was added and vortexed to dissolve oxygen in solution. 100 ul enzyme extract from​ A. nidulans​ then added. 
Reaction mixture placed in a 37℃ metal bead bath for 60 minutes. MPA added at 10% v/v before readout. 
Note the shift in the HGA peak away from 290 nm most likely due to the addition of the acid.  
  
     These results lead to the hypothesis that perhaps the enzyme extract was not concentrated 
enough to cause detectable conversion of HGA to MAA in the full scale reaction. According to 
Dr. Fernández-Cañón, the concentration of the extract should be around 10 mg/ml. In order to 
determine the concentration of the experimental extract, a colorimetric protein quantification 
assay was used. The Bio-Rad assay uses Coomassie brilliant blue G-250 that binds to basic side 
chains on proteins in a sample and changes color at different protein concentrations. A set of 
controls with a known concentration of protein in a series of dilutions was compared to the 
experimental sample and the dilution that matched the experimental sample was taken as a rough 
estimate of the protein concentration of the sample. The concentration of the experimental 
extract appeared to be close to 1.5 mg/ml, a drastic dilution from the 10 mg/ml expected. It was 
therefore determined that further concentration of the sample may have been necessary in order 
to obtain better activity in the enzyme assay.  
     Concentration of the extract was accomplished using the Amicon Ultra Centrifuge Filtration 
system. The filter used had a molecular weight cutoff (MWCO) of 5,000 da. 11 ml of the enzyme 
extract was added to the filter and it was spun at 5,000 x g at 4℃ for 45 minutes to obtain a 10x 
concentration. The protein quantification assay was then rerun and the new concentration of 
protein was determined to be around 6 mg/ml. Ideally, the sample would have been spun until 
the concentration was closer to 10  mg/ml, however the protein began to precipitate out of 
solution, so the lower concentration was kept.  
      The new concentration was then used to rerun the assay under the new standard conditions. 
This assay once again came up with no activity after 60 minutes (Figure 9). This was the last 
assay run before the write up of this report. The lack of activity in this case could possibly be due 
to the killing off of the enzyme during a series of freezes and thaws, or due to precipitation 
during the concentration process. 
 
 
Figure 9. Change in absorbance at 330 nm over time of enzyme assay using extract concentrated in Amicon 
column.​ ​2 mM HGA, 1 mM ascorbate, 50 uM FeS0​4 ​and potassium phosphate buffer pH 7, added to reaction 
tube before oxygen gas was added and vortexed to dissolve oxygen in solution. 100 ul enzyme extract from​ A. 
nidulans​ then added. Reaction mixture placed in a 37℃ metal bead bath for 60 minutes. MPA added at 10% 
v/v before readout.  
 
Discussion 
     The failure of the assay to indicate any useful activity lead to several different troubleshooting 
approaches. The lack of activity could have been due to roughly three different error sources. 
The first approach assumed that something went wrong with the protein extract itself. This could 
have been an ineffective extraction method, denaturing of the enzyme during purification, or 
simply that there was not enough of the enzyme in the first place to reach levels of activity 
necessary for detection in the spectrophotometer. The second approach assumed an error in the 
reaction mixture, such as an improperly prepared buffer that is ineffective at maintaining optimal 
pH, or too much or too little of one of the cofactors such as Fe2+ ions that are necessary for the 
enzyme to function. Finally,  potential environmental influences such as temperature were 
addressed. Any or all of these error sources could be operating during any given iteration of the 
protocol. Troubleshooting methods were aimed at each of these three categories. Altering the 
growth conditions of the fungus and modifying the enzyme extraction methods had no effect on 
the quantitative conversion of HGA to MAA (Figure 5). Likewise obtaining the enzyme from 
mouse liver instead of fungi did not improve the performance of the assay (Figure 6). A extract 
from newer fungal samples showed promise in the initial phases, but its activity diminished over 
the course of several assays, even after concentrating the extract in an attempt to increase activity 
(Figure 7, 8, 9). Troubleshooting strategies aimed at the reaction mixture or environmental 
impacts also failed to produce extracts with higher yields of MAA. Since the only partly 
successful assay was run under the original reaction conditions, with the literature recommended 
buffer system it seems most likely that the source of error in the experiment is that there has not 
yet been a source of enzyme that provides high enough activity for quantitative conversion to 
take place.  
     The next step is to continue to pursue better enzyme sources. Dr. Fernández-Cañón provided 
us with new mycelia that have been enzymatically induced and harvested. These newer spores 
are a promising source of enzyme as is apparent by the partial success of the reaction with the 
first use of the protein extract made from the same source (Figure 7). Another future approach 
could potentially be an attempt to clone the ​hgd​ gene from​ A. nidulans​ ​into an organism that 
would lend itself to a less fraught induction and extraction process.  
     The original intent of this thesis was to seek out ways to optimize and improve the original 
FAA synthesis protocol. Due to the difficulty experienced herein, this is still a valid research 
goal. If the protocol can be successfully replicated, then ways to streamline this process are well 
worth pursuing in order to have stores of FAA to be used in assays testing CEHPOBA, a drug 
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